chronic idiopathic myelofibrosis (cIMF)
Showing 1 - 25 of >10,000
Chronic Myeloproliferative Disorders, Leukemia, MDS Trial in Cleveland (ascorbic acid, arsenic trioxide, dexamethasone)
Completed
- Chronic Myeloproliferative Disorders
- +3 more
- ascorbic acid
- +3 more
-
Cleveland, Ohio
- +1 more
Jul 23, 2020
68Ga-FAPI PET/CT Imaging for Diagnosis, Grading, and Efficacy
Recruiting
- Primary Myelofibrosis
- 68Ga FAPI PET/CT
-
Xiamen, Fujian, ChinaBing Xu
Nov 28, 2023
Assess the Safety of Fedratinib in Korean Myelofibrosis
Recruiting
- Primary Myelofibrosis
- +2 more
-
Seoul, Korea, Republic ofBristol-Myers Squibb YH
Oct 3, 2023
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive,
Completed
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- +4 more
- Eltrombopag Olamine
-
Houston, TexasM D Anderson Cancer Center
Jan 4, 2022
Pre-fibrotic Myelofibrosis Trial in Taipei, Taiwan, 100 (Ropeginterferon Alfa-2B Prefilled Syringe [Besremi])
Recruiting
- Pre-fibrotic Myelofibrosis
- Ropeginterferon Alfa-2B Prefilled Syringe [Besremi]
-
Taipei, Taiwan, 100, TaiwanNational Taiwan University Hospital
Feb 7, 2023
Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Post-polycythemia Vera Myelofibrosis Trial in Ipoh (NS-018,
Recruiting
- Primary Myelofibrosis
- +2 more
- NS-018
- Best Available Therapy
-
Worcester, Massachusetts
- +16 more
Oct 31, 2022
Myelofibrosis Trial in Saint Louis (Fostamatinib, Ruxolitinib)
Recruiting
- Myelofibrosis
-
Saint Louis, MissouriWashington University School of Medicine
Oct 26, 2022
Myelofibrosis Trial in Italy (A: Fludarabine + Busulphan, B: Fludarabine + Thiotepa)
Completed
- Myelofibrosis
- A: Fludarabine + Busulphan
- B: Fludarabine + Thiotepa
-
Alessandria, Italy
- +20 more
Aug 19, 2021
Adenosine Deaminase and Immunoglobulin E in Chronic Spontaneous
Not yet recruiting
- Chronic Spontaneous Urticaria
- Adenosine deaminase serum level
- IgE antibodies serum level
- (no location specified)
Aug 7, 2023
Myelofibrosis Trial in Houston (Long-term Follow-up, Quality-of-Life Assessment, Ruxolitinib)
Active, not recruiting
- Myelofibrosis
- Long-term Follow-up
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Sep 7, 2022
Myelofibrosis Trial in China (TQ05105 Tablets, TQB3617 Capsules)
Not yet recruiting
- Myelofibrosis
- TQ05105 Tablets
- TQB3617 Capsules
-
Guangzhou, Guangdong, China
- +19 more
Nov 7, 2023
Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis Trial in Worldwide
Recruiting
- Primary Myelofibrosis
- +2 more
- Pacritinib
- Physician's Choice medications
-
Birmingham, Alabama
- +151 more
Aug 22, 2022
Myelofibrosis Trial in France (Clonal architecture determination)
Not yet recruiting
- Myelofibrosis
- Clonal architecture determination
-
Angers, France
- +6 more
Jan 24, 2023
Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Primary Myelofibrosis, Secondary Myelofibrosis Trial in Houston
Completed
- Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase
- +2 more
- Laboratory Biomarker Analysis
- +2 more
-
Houston, TexasM D Anderson Cancer Center
May 27, 2022
Idiopathic Pulmonary Fibrosis Trial in Hialeah Gardens (20mM sodium pyruvate nasal spray, Saline Placebo control nasal spray)
Recruiting
- Idiopathic Pulmonary Fibrosis
- 20mM sodium pyruvate nasal spray
- Saline Placebo control nasal spray
-
Hialeah Gardens, FloridaFamily First Medical Research Center
Sep 16, 2023
Accelerated/Blast-phase Myeloproliferative Tumor, Chronic-phase Myelofibrosis, IDH2 Mutation Trial in Canada, United States
Recruiting
- Accelerated/Blast-phase Myeloproliferative Neoplasm
- +2 more
-
Scottsdale, Arizona
- +10 more
May 9, 2022
Myelofibrosis Trial in Hangzhou (Jaktinib, Placebo to match Hydroxycarbamide, Hydroxycarbamide Tablets)
Recruiting
- Myelofibrosis
- Jaktinib
- +3 more
-
Hangzhou, Zhejiang, ChinaThe First Affiliated Hospital of Medical School of Zhejiang Univ
Nov 28, 2022